INVESTOR CENTRE

Dear Investors,

Welcome to Myopharm, a clinical-stage company with a strong clinical pipeline in developing targeted therapies for multiple chronic diseases.

Myopharm has expert management coupled with an efficient business model and an ambitious roadmap, with R&D and manufacturing at the core of our development. Myopharm believes in long-term and sustainable partnerships.

With the Type 2 diabetes population expected to double to over 600 million worldwide by 2045, and the diabetes market expected to grow from $20.4B to over $58.7B within 2025, we believe that your health cannot afford to wait.

Share Registry

Corporate Governance

Shareholder Updates

06/08/2025

TriGlytza® achieves significant reduction in HbA1c % in Pre-Clinical Type 2 Diabetes

Read Announcement

25/07/2025

Myopharm Appoints Dr Trevor Lockett to the Board of Directors

Read Announcement

16/07/2025

Myopharm Clinical & Preclinical Trials and Partnership Update

Read Announcement

20/06/2025

3-YEAR PARTNERSHIP SIGNED WITH DIABETES AUSTRALIA

Read Announcement

13/06/2025

2024 Annual Report & Financial Statements

Read Announcement

07/05/2025

MARCH 2025 QUARTERLY REPORT

Read Announcement

17/03/2025

Dr George Tachas and Advait Padhye joins Myopharm’s Scientific Team

Read Announcement

06/02/2025

Myopharm strengthens clinical development team with appointment of Tamara Miller

Read Announcement

Myopharm

Myopharm Limited
Levels 1, 2 & 3 60 Martin Place
Sydney New South Wales 2000

Our Company

Overview

Investor Welcome

Contact Us

News & Media

Store

Subscribe to our email alerts

Karinza Phoenix MBA GAICD

Executive Chair & Founding CEO

Ms Phoenix has more than 24 years of executive and commercial experience in pharmaceutical, veterinary and capital markets sectors, inclusive of holding operational and marketing roles at Pfizer, Novartis and Zoetis.

Ms Phoenix has a successful track record of product development, registration and marketing launches, incorporating successful commercialisation of numerous market leading blockbuster medicines.

Ms Phoenix has served on the Myopharm Board of Directors for 4 years and has invested in almost all capital raises to date, while focussing on expanding Myopharm’s clinical and commercial initiatives.

Milton Grannatt PhD

Founding Non – Executive Director

Mr Grannatt has more than 35 years’ of broad experience in global pharmaceuticals.

Previously Vice President of Finance, Sterling Winthrop and Vice President of Global Business Development and Licensing at Novartis, Mr Grannatt was additionally a Non-Executive Director at SymBio Pharmaceuticals Limited.

Mr Grannatt is currently a valued Advisor to Myopharm and a number of biotechnology start-ups.

Tsutomu (Tom) Abe LLB

Non–Executive Director

Mr Abe has over 30 years extensive international experience as both General Counsel to Japanese global corporations and as an executive in the global pharmaceuticals industry in business development, licensing and alliance management.

Previously Mr Abe was General Counsel at Fast Retailing Co., Ltd and Kokuyo Co., Ltd and Corporate officer in charge of Global Business Development and Global Alliance Management at SymBio Pharmaceuticals Limited.

Currently Mr Abe is COO at TAK-Circulator Corporation, CLO at nonpi Inc and CEO at Askleon Co. Ltd. Mr Abe holds a Bachelor of Law from Keio University.

Dr Trevor Lockett PhD

Non–Executive Director

A molecular biologist by training, Trevor had a distinguished scientific career with CSIRO, in the latter years leading the Personalised Health Group within CSIRO’s Health & Biosecurity Business Unit. Here he directed research supporting the development of new diagnostic tests for the early detection of colorectal cancer and diet and lifestyle approaches to promoting gastrointestinal health.

In 2017 he joined Rhythm Biosciences as the company’s founding Managing Director, contributing to the successful ASX listing of the company in December 2017. He served as a member of Rhythm’s Board from its inception in 2017, first as an executive director, then as a non-executive Director, retiring from the Board in November of 2024. He was part time Technical Director at Rhythm from July 2020 to December 2023 and continues to consult to the company. He also served as a non-executive director on the board of the private company, Juno Healthcare, from January to December of 2023.

Trevor is an inventor on ten patent and patent application families, is an author on over 100 peer reviewed publications in the scientific literature and is a Member of the Australian Institute of Company Directors.

Dr George Tachas PhD Dip IP Law

Chief Scientific Officer

Dr Tachas brings 26 years of research, development and commercialization experience having been involved in early stage in-licensing, generating IP and out-licensing multiple clinic stage assets.

With strong applied immunology skills in biomedical science as an inventor of over 110 granted patents, and 10 academic publications in the last decade including three in clinical trials in autoimmune disease and endocrinology, Dr Tachas’ skills have generated successful preclinical animal data in a dozen animal models generating IP.

Dr Tachas’ His career highlights include setting up an early-stage biotech company in Australia and leadership roles as Principal Scientist at ASX-listed Percheron Therapeutics, and previously Director of Drug Discovery and Patents at Antisense Therapeutics Ltd.

Tamara Miller BSc PMP CPPM DipBus

Head of Clinical Development

Ms Miller has had a successful career in clinical research spanning more than 22 years.

Coupled with a Biomedical Science degree, Tamara holds project management certification, and she has worked in diverse roles in medical research, project and program management, product development, and strategic operations management across pharmaceutical and biotechnology companies and CROs.

Ms Miller has lived and worked in the US and the UK whilst holding leadership positions in start-up Biotechs, and her most recent role in this space was as Snr VP of Product Development at Actinogen Medical.

Tamara has broad experience in drug development including pre-clinical and clinical operations, global regulatory affairs, chemistry manufacturing & control (CMC), data management and biostatistics, pharmacovigilance, and medical writing.

Advait Padhye BSc MBiomedSc

Research Associate

Mr Padhye is an accomplished biomedical scientist with more than 4 years of experience in preclinical and clinical research, specializing in drug discovery, biomarker analysis, and translational medicine.

With a Master’s degree in Biomedical Science from the University of Melbourne and a strong interest in neuropharmacology and regenerative medicine, Mr Padhye is committed to advancing innovative therapeutic solutions and improving health outcomes through cutting-edge science, and his expertise includes experimental design, data analysis, and experimental techniques such as immunohistochemical staining, fluorescence microscopy, and tissue processing.

Steven Jackson BEc CPA

Chief Financial Officer

Mr Jackson has over 15 years of experience in accounting and corporate governance roles across both listed and unlisted companies. He is a member of CPA Australia and has served as CFO for several ASX-listed companies, gaining extensive expertise across a diverse range of industries.

Mr Jackson is a member of CPA Australia who graduated from the University of Western Australia in 2008 with a Bachelor of Economics majoring in International Business Economics and Money and Banking.

ARKAY Therapeutics LLC

Scientific Advisory Board

ARKAY Therapeutics LLC are a group of globally renowned Professors, Scientists, Practising and Academic Endocrinologists and Regulatory Affairs specialists with extensive clinical trial experience in both big pharmaceutical and private companies. ARKAY’s team are based across the United States of America.

Prof David Church BVSc PhD MACVSc FHEA MRCVS

Scientific Advisory Board

Prof Church graduated from The University of Sydney, after graduation he was appointed as a clinical instructor at The University of Sydney and completed his PhD programme in the Faculty of Medicine looking at various aspects of the pathophysiology of diabetes mellitus.

Later appointed as a member of faculty in small animal medicine at The University of Sydney, Prof Church rose to become Hospital Director of The University Veterinary Centre.

In 2001 Prof Church was appointed Chair of Small Animal Studies at the Royal Veterinary College and head of the newly formed Department of Veterinary Clinical Sciences. The department grew to be one of the largest and successful clinical departments in the world with substantial research grant funding. Prof Church maintains an interest in endocrinology and his current research interests include insulin resistance states in diabetes mellitus and the use of ‘big data’ from general practice for managing animal health and welfare.

Prof Church is the author of over 150 scientific articles, numerous book chapters, and he is editor of the highly successful textbook Small Animal Clinical Pharmacology.